SCOPUS 정보 검색 플랫폼 - 논문 보기

메뉴 건너뛰기

Volumn 5, Issue 2, 2016, Pages

A century of oncolysis evolves into oncolytic immunotherapy

(2) Hemminki, O a,b Hemminki, A a,c,d

a UNIVERSITY OF HELSINKI (Finland)

b Kotka Central Hospital (Finland)

c HELSINKI UNIVERSITY CENTRAL HOSPITAL (Finland)

d TILT Biotherapeutics Ltd (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84959377628 PISSN: 21624011 EISSN: 2162402X Source Type: Journal
DOI: 10.1080/2162402X.2015.1074377 Document Type: Article

Times cited : (17)

References (10)

1
- 84933586864
- Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
- 26014293
- R.H.Andtbacka, H.L.Kaufman, F.Collichio, T.Amatruda, N.Senzer, J.Chesney, K.A.Delman, L.E.Spitler, I.Puzanov, S.S.Agarwala et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015 Sep 1; 33(25):2780-8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377 and DOI: 10.18632/oncotarget.2901
- J Clin Oncol. 2015 Sep 1; 33(25):2780-8;
- Andtbacka, R.H.¹ Kaufman, H.L.² Collichio, F.³ Amatruda, T.⁴ Senzer, N.⁵ Chesney, J.⁶ Delman, K.A.⁷ Spitler, L.E.⁸ Puzanov, I.⁹ Agarwala, S.S.¹⁰

2
- 84867037132
- Ad3-hTERT-E1A, a fully Serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer
- O.Hemminki, I.Diaconu, V.Cerullo, S.K.Pesonen, A.Kanerva, T.Joensuu, K.Kairemo, L.Laasonen, K.Partanen, L.Kangasniemi et al. Ad3-hTERT-E1A, a fully Serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther. 2012 Sep; 20(9):1821-30; PMID:22871667; http://dx.doi.org/10.1038/mt.2012.115
- (2012) Mol Ther
- Hemminki, O.¹ Diaconu, I.² Cerullo, V.³ Pesonen, S.K.⁴ Kanerva, A.⁵ Joensuu, T.⁶ Kairemo, K.⁷ Laasonen, L.⁸ Partanen, K.⁹ Kangasniemi, L.¹⁰

3
- 84924280819
- Immunological data from cancer patients treated with Ad5/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy
- 25714011
- O.Hemminki, S.Parviainen, J.Juhila, R.Turkki, N.Linder, J.Lundin, M.Kankainen, A.Ristimaki, A.Koski, I.Liikanen et al. Immunological data from cancer patients treated with Ad5/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy. Oncotarget 2015; 6:4467-81; PMID:25714011
- (2015) Oncotarget , vol.6 , pp. 4467-4481
- Hemminki, O.¹ Parviainen, S.² Juhila, J.³ Turkki, R.⁴ Linder, N.⁵ Lundin, J.⁶ Kankainen, M.⁷ Ristimaki, A.⁸ Koski, A.⁹ Liikanen, I.¹⁰

4
- 84938513665
- Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
- 25949903
- I.Liikanen, A.Koski, M.Merisalo-Soikkeli, O.Hemminki, M.Oksanen, K.Kairemo, T.Joensuu, A.Kanerva, A.Hemminki. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology 2015; 4:e989771; PMID:25949903; http://dx.doi.org/10.4161/2162402X.2014.989771
- (2015) Oncoimmunology , vol.4 , pp. 989771
- Liikanen, I.¹ Koski, A.² Merisalo-Soikkeli, M.³ Hemminki, O.⁴ Oksanen, M.⁵ Kairemo, K.⁶ Joensuu, T.⁷ Kanerva, A.⁸ Hemminki, A.⁹

5
- 84922262706
- Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors
- 25381801
- A.Kanerva, A.Koski, I.Liikanen, M.Oksanen, T.Joensuu, O.Hemminki, J.Palmgren, K.Hemminki, A.Hemminki. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors. Mol Ther 2015; 23:321-9; PMID:25381801; http://dx.doi.org/10.1038/mt.2014.218
- (2015) Mol Ther , vol.23 , pp. 321-329
- Kanerva, A.¹ Koski, A.² Liikanen, I.³ Oksanen, M.⁴ Joensuu, T.⁵ Hemminki, O.⁶ Palmgren, J.⁷ Hemminki, K.⁸ Hemminki, A.⁹

6
- 77953083925
- Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors
- 20501623
- P.Nokisalmi, S.Pesonen, S.Escutenaire, M.Sarkioja, M.Raki, V.Cerullo, L.Laasonen, R.Alemany, J.Rojas, M.Cascallo et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 2010; 16:3035-43; PMID:20501623; http://dx.doi.org/10.1158/1078-0432.CCR-09-3167
- (2010) Clin Cancer Res , vol.16 , pp. 3035-3043
- Nokisalmi, P.¹ Pesonen, S.² Escutenaire, S.³ Sarkioja, M.⁴ Raki, M.⁵ Cerullo, V.⁶ Laasonen, L.⁷ Alemany, R.⁸ Rojas, J.⁹ Cascallo, M.¹⁰

7
- 84878074018
- Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus
- 23493351
- A.Kanerva, P.Nokisalmi, I.Diaconu, A.Koski, V.Cerullo, I.Liikanen, S.Tahtinen, M.Oksanen, R.Heiskanen, S.Pesonen et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013; 19:2734-44; PMID:23493351; http://dx.doi.org/10.1158/1078-0432.CCR-12-2546
- (2013) Clin Cancer Res , vol.19 , pp. 2734-2744
- Kanerva, A.¹ Nokisalmi, P.² Diaconu, I.³ Koski, A.⁴ Cerullo, V.⁵ Liikanen, I.⁶ Tahtinen, S.⁷ Oksanen, M.⁸ Heiskanen, R.⁹ Pesonen, S.¹⁰

8
- 84887267740
- Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells
- 24204268
- Z.Z.Lu, H.Wang, Y.Zhang, H.Cao, Z.Li, P.Fender, A.Lieber. Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells. PLoS pathogens 2013; 9:e1003718; PMID:24204268; http://dx.doi.org/10.1371/journal.ppat.1003718
- (2013) PLoS pathogens , vol.9 , pp. 1003718
- Lu, Z.Z.¹ Wang, H.² Zhang, Y.³ Cao, H.⁴ Li, Z.⁵ Fender, P.⁶ Lieber, A.⁷

9
- 84890519990
- [(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer
- 24099555
- A.Koski, H.Ahtinen, H.Liljenback, A.Roivainen, A.Koskela, M.Oksanen, K.Partanen, L.Laasonen, K.Kairemo, T.Joensuu et al. [(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. Hum Gene Ther 2013; 24:1029-41; PMID:24099555; http://dx.doi.org/10.1089/hum.2013.123
- (2013) Hum Gene Ther , vol.24 , pp. 1029-1041
- Koski, A.¹ Ahtinen, H.² Liljenback, H.³ Roivainen, A.⁴ Koskela, A.⁵ Oksanen, M.⁶ Partanen, K.⁷ Laasonen, L.⁸ Kairemo, K.⁹ Joensuu, T.¹⁰

10
- 84898001762
- In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders
- 24248808
- O.Hemminki, R.Immonen, J.Narvainen, A.Kipar, J.Paasonen, K.T.Jokivarsi, H.Yli-Ollila, P.Soininen, K.Partanen, T.Joensuu et al. In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. Inter J Cancer J Inter du Cancer 2014; 134:2878-90; PMID:24248808;http://dx.doi.org/10.1002/ijc.28615
- (2014) Inter J Cancer J Inter du Cancer , vol.134 , pp. 2878-2890
- Hemminki, O.¹ Immonen, R.² Narvainen, J.³ Kipar, A.⁴ Paasonen, J.⁵ Jokivarsi, K.T.⁶ Yli-Ollila, H.⁷ Soininen, P.⁸ Partanen, K.⁹ Joensuu, T.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.